image
Healthcare - Biotechnology - OTC - US
$ 0.0004
0.000003 %
$ 21.8 K
Market Cap
None
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BTTX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.0004 USD, Better Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BTTX stock under the base case scenario is HIDDEN Compared to the current market price of 0.0004 USD, Better Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BTTX stock under the best case scenario is HIDDEN Compared to the current market price of 0.0004 USD, Better Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BTTX

image
$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0Nov '24Nov '24Dec '24Dec '2420252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25
FINANCIALS
0 REVENUE
0.00%
-38.3 M OPERATING INCOME
-25.20%
-39.8 M NET INCOME
1.43%
-28.9 M OPERATING CASH FLOW
6.13%
-1.18 M INVESTING CASH FLOW
-10.18%
5.28 M FINANCING CASH FLOW
7205.20%
0 REVENUE
0.00%
-5.34 M OPERATING INCOME
23.97%
-5.86 M NET INCOME
22.76%
-5.94 M OPERATING CASH FLOW
-16.83%
66 K INVESTING CASH FLOW
113.12%
6.28 M FINANCING CASH FLOW
9.81%
Balance Sheet Better Therapeutics, Inc.
image
Current Assets 18.4 M
Cash & Short-Term Investments 15.7 M
Receivables 0
Other Current Assets 2.71 M
Non-Current Assets 4.5 M
Long-Term Investments 0
PP&E 121 K
Other Non-Current Assets 4.38 M
68.60 %11.79 %19.07 %Total Assets$22.9m
Current Liabilities 13.5 M
Accounts Payable 3.04 M
Short-Term Debt 4.53 M
Other Current Liabilities 5.93 M
Non-Current Liabilities 10.3 M
Long-Term Debt 10.3 M
Other Non-Current Liabilities 0
12.73 %19.01 %24.86 %43.40 %Total Liabilities$23.8m
EFFICIENCY
Earnings Waterfall Better Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 2.73 M
Gross Profit -2.73 M
Operating Expenses 38.3 M
Operating Income -38.3 M
Other Expenses 1.5 M
Net Income -39.8 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)0(3m)(3m)(38m)(38m)(1m)(40m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
4422.69% ROE
4422.69%
-173.30% ROA
-173.30%
-273.72% ROIC
-273.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Better Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20202020Jul '20Jul '2020212021Jul '21Jul '2120222022Jul '22Jul '2220232023
Net Income -39.8 M
Depreciation & Amortization 2.73 M
Capital Expenditures -1.18 M
Stock-Based Compensation 1.82 M
Change in Working Capital 6.27 M
Others 4.76 M
Free Cash Flow -30.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Better Therapeutics, Inc.
image
BTTX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Better Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc. NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc. businesswire.com - 11 months ago
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company's securities are subject to delisting from the Nasdaq Stock Market u. businesswire.com - 1 year ago
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its. businesswire.com - 1 year ago
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showca. businesswire.com - 1 year ago
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). accesswire.com - 1 year ago
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases. zacks.com - 1 year ago
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Breakthrough status is reserved for technol. businesswire.com - 1 year ago
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation's leading Pharmacy Benefit Managers (PBMs) negotiating on behalf of over 70 million lives in the US. The rebate agreement, effective January 1, 2024, applies to the PBM's commercial book of business and provides plan participants of the PB. businesswire.com - 1 year ago
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study, titled "Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes'' has been published in Advances in Therapy, a prominent peer-reviewed. businesswire.com - 1 year ago
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a partnership to integrate Better Therapeutics' AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko's diabetes management platform. This collaboration will enable healthcare providers in the United States who. businesswire.com - 1 year ago
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD and NASH. MAS. businesswire.com - 1 year ago
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx. The company launched AspyreRx in October of this year, after receiving U.S. Food and Drug Administration (FDA) authorization in July for the treatment of adults wi. businesswire.com - 1 year ago
8. Profile Summary

Better Therapeutics, Inc. BTTX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 21.8 K
Dividend Yield 0.00%
Description Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Contact 548 Market Street, San Francisco, CA, 94104 https://www.bettertx.com
IPO Date March 17, 2021
Employees 54
Officers Ms. Kristin Wynholds Chief Product Officer Mr. Frank L. Karbe M.B.A. Interim Chief Financial Officer & Director Ms. Angela Willis Senior Vice President of Market Access Dr. Mark A. Berman M.D. Chief Medical Officer Leslie Miller Controller Ms. Jessica Meng Chief Commercial Officer Mr. David P. Perry M.B.A. Co-Founder & Executive Chairman Mr. Andres Camacho Senior Vice President of Technology & Head of Engineering